Alixorexton, a Novel Oral Orexin 2 Receptor Agonist, Shows Promising Safety and Efficacy in Narcolepsy Type 1: Insights from the Vibrance-1 Phase 2 Trial
The Vibrance-1 phase 2 trial demonstrates that once-daily oral alixorexton significantly improves wakefulness and reduces cataplexy in narcolepsy type 1, with a favorable safety profile supporting phase 3 evaluation.